|
AU2011203318A1
|
|
Simultaneous quantification of nucleic acids in diseased cells
|
|
MX2011006891A
|
|
Nucleoside phosphoramidates.
|
|
BRPI0922508A2
|
|
Nucleoside Analogs
|
|
TW201031675A
|
|
Synthesis of purine nucleosides
|
|
US2009318380A1
|
|
2',4'-substituted nucleosides as antiviral agents
|
|
WO2009052050A1
|
|
Dioxolane thymine phosphoramidates as anti-hiv agents
|
|
US2010016251A1
|
|
Nucleoside phosphoramidate prodrugs
|
|
US2008280846A1
|
|
2′,3′-dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections
|
|
AU2007240180A1
|
|
Simultaneous quantification of nucleic acids in diseased cells
|
|
WO2007097991A2
|
|
Methods and kits for dosing of antiviral agents
|
|
NZ567272A
|
|
Modified 4'-nucleosides as antiviral agents
|
|
NZ554442A
|
|
Preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
|
|
NZ584752A
|
|
Preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidines and purines and their derivatives
|
|
CA2574651A1
|
|
Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives
|
|
CA2548144A1
|
|
Dosing methods for .beta.-d-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine antiviral therapy
|
|
WO2005018330A1
|
|
Dosing regimen for flaviviridae therapy
|
|
BRPI0408846A
|
|
compounds for the treatment of flaviviridae infections
|
|
KR20050052461A
|
|
Processes for preparing 1,3-dioxolane nucleosides
|
|
SG174624A1
|
|
Compounds with the bicyclo[4.2.1]nonane system for the treatment of flaviviridae infections
|
|
CA2743451A1
|
|
Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation
|
